Longboard Pharmaceuticals Update Following Investor Day
Recently, H.C. Wainwright increased its price target for Longboard Pharmaceuticals Inc (NASDAQ: LBPH) to $80 from $60, while still maintaining a Buy rating. This change follows the company’s Investor & Analyst Day, where it provided important updates about its treatment program for developmental and epileptic encephalopathies (DEEs).
Highlighting Bexicaserin and Phase 3 DEE Program
At the Investor Day, Longboard focused on bexicaserin (LP352). This oral treatment acts as a highly selective superagonist for the 5-HT2C receptor subtype. The company detailed its Phase 3 DEE initiative, which includes multiple studies such as DEEp OCEAN, DEEp SEA, and DEEp OLE. Notably, this program has expanded to cover a broader range of DEEs than previously anticipated.
Strategic Changes and Broader Focus
This expanded focus in Longboard's DEE program marks a significant strategic shift from its previous approach, which was centered on specific indications. This change resulted from productive discussions with the FDA after the end of Phase 2 and the granting of Breakthrough Therapy Designation (BTD). This designation is expected to simplify the development and review process for the drug, allowing for quicker market access.
Analysts’ Positive Perspective
Due to the comprehensive nature of the DEE program and a better understanding of the condition, paired with favorable regulatory news, H.C. Wainwright laid out a solid justification for its revised price target. The firm reiterated its positive outlook on Longboard's potential and reaffirmed the Buy rating, showing trust in the company’s progress in DEE therapies.
Other Views on Longboard from Analysts
In recent updates, Baird expressed its ongoing support by keeping an Outperform rating along with a price target of $60. This comes on the heels of Longboard's detailed plans for Phase 3 trials for bexicaserin, a promising option for DEEs. These clinical trials are expected to start around the end of September, with top-line results anticipated by late 2026.
New Coverage and Development Plans
Truist Securities has also begun to cover Longboard, assigning it a Buy rating and a price target of $60. Their analysis indicates that bexicaserin could outperform current epilepsy treatments. Besides bexicaserin, Longboard is also developing LP659, which targets CNS, inflammation, and immunity.
Market Reactions and Future Expectations
Following the FDA granting BTD for bexicaserin, Baird reacted by increasing Longboard’s price target from $36 to $60. Similarly, Citi upgraded its target from $40 to $45 while keeping a Buy recommendation, particularly after the FDA approved a Phase 3 study for the drug candidate.
Looking Ahead: Upcoming Initiatives and Trials
As we move forward, Longboard plans to kick off a Phase 3 program by the end of 2024 and expects to release Phase 1 data for LP659 in the second quarter of 2024. These initiatives reflect a strong commitment to addressing significant unmet needs within the epilepsy treatment landscape.
Investing Insights on Longboard Pharmaceuticals
As Longboard Pharmaceuticals Inc (NASDAQ: LBPH) advances its efforts in DEE treatments, it’s wise for investors to monitor the real-time developments. The company currently boasts a market capitalization of $1.07 billion and has undergone considerable market fluctuations, reflecting a year-to-date return of 357.38%. This growth emphasizes a dynamic outlook regarding Longboard's future potential.
Considerations on Financial Health
It's worth noting that Longboard has more cash than debt at present. This financial standing may ease some concerns, providing essential flexibility for ongoing clinical projects. However, recent analyses show that four analysts have lowered their earnings expectations, suggesting some caution regarding short-term profitability. Despite this, Longboard's stock has shown resilience, especially over the last three months.
Frequently Asked Questions
What is the new price target for Longboard Pharmaceuticals?
The new price target for Longboard Pharmaceuticals is set at $80, raised from the previous $60.
What drug is Longboard focusing on for DEEs treatment?
Longboard is focusing on bexicaserin (LP352) as a treatment for developmental and epileptic encephalopathies.
What has been the market reaction to Longboard's recent news?
Longboard has experienced significant volatility, with a year-to-date total return of 357.38% reflecting strong investor interest.
Are there other drugs in development by Longboard Pharmaceuticals?
Yes, alongside bexicaserin, Longboard is developing LP659, which focuses on CNS, inflammation, and immunity indications.
What does the Breakthrough Therapy Designation mean for Longboard?
This designation can expedite the development and review of bexicaserin, potentially speeding up its path to market.
